Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms.

Berger M, Pock M, Reiss M, Röhling G, Czypionka T. (2022) Int J Health Econ Manag

Cost-effectiveness of Positive Memory Training (PoMeT) for the treatment of depression in schizophrenia.

Simon J, Kiss N, Korrelboom K, Kingdon D, Wykes T, Phiri P, et al. (2022) Int J Environ Res Public..

Exploring the over-time, multifaceted impacts of three Covid-19 lockdowns on aspects of capability, wellbeing and mental health across vulnerabilities in Austria.

Helter T, Laszewska A, Simon J. (2022) Scientific Reports

ASPHER Statement: Planning for winter 2022-23.

Middleton J, Davidovitch N, Barros H, Lopes H, Moreno JMM, Mason-Jones AJ, et al. (2022) Public..

ASPHER Statement: Facing the fourth winter of the COVID-19 pandemic.

Hrzic R, Davidovitch N, Barros H, Lopes H, Moreno JMM, Mason-Jones AJ, et al. (2022) Public Health..

Conceptual framework for optimised proxy value set selection through supra-national value set development for the EQ-5D instruments.

Łaszewska A, Sajjad A, Busschbach J, Simon J, Hakkaart-van Roijen L. (2022) PharmacoEconomics.

The excess resource use and costs of physical comorbidities in patients with mental health disorders: A systematic review and meta analysis.

Simon J, Wienand D, Park A-L, Wippel C, Mayer S, Heilig D, et al. (2022) Eur Neuropsychopharmacol.